Study Summary
This study is a Phase I trial using an advanced lentiviral vector to deliver a functional gene for human clotting factor IX into patients with hemophilia B, to evaluate the safety and efficacy of infusion of lentiviral gene modified autologous stem cells in patients.
Interested in this trial?
Submit an InquiryInterventions
YUVA-GT-F901BIOLOGICAL
Lentiviral factor IX gene modified autologous hematopoietic and mesenchymal stem cells
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Shenzhen Geno-immune Medical Institute | Shenzhen | Guangdong | China |